Baxter recalls Preflucel flu vaccine

Baxter Pharmaceuticals recently issued an immediate recall of two batches of its Preflucel flu vaccine in the United Kingdom.

Baxter has directed healthcare providers that, while the Class 1, or immediate action, recall covers only two batches, as a precaution, none of the vaccine should be used, according to

The callback covers approximately 300,000 doses and was issued because a greater number of adverse reactions were reported than were expected.

"The vaccine should no longer be used and any remaining stock [of the recalled batches] should be returned to the original supplier for credit," U.K. Medicines and Healthcare products Regulatory Agency announced, according to "No further Preflucel of any batch should be administered at this time."

The adverse reaction reports detail mostly mild and short-lived adverse effects in those who received the vaccine. They are considered consistent with the type seen in most flu vaccines but greater in number. Baxter and MHRA are investigating the cause, which remains unknown.

Baxter has not announced when additional batches might be available, but enough alternative low-egg-content vaccines are on the market that supply is not expected to be interrupted.